Evidence map›Paper›PMID 29700418›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2018

SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma.

David L Kolin, Fei Dong, Michele Baltay, Neal Lindeman, Laura MacConaill, Marisa R Nucci, Christopher P Crum, Brooke E Howitt

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 163 citations in OpenAlex.

  1. Article
  2. Review
  3. An update on the role of SMARCA4 deficiency in gynecological neoplasms: how and where.Virchows Archiv : an international journal of pathology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. New histopathological and molecular findings in gynecological cancers.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025
    Review
  9. Article
  10. Towards a greater understanding of uterine sarcomas.Case reports in women's health · 2025
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Translational Aspects of Epithelioid Sarcoma: Current Consensus.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Review
  17. Review
  18. Article
  19. Esophageal carcinoma withTranslational gastroenterology and hepatology · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

David L KolinDivision of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.ORCID http://orcid.org/0000-0002-7631-6525
Fei DongDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Michele BaltayDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Neal LindemanDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Laura MacConaillDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Marisa R NucciDivision of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Christopher P CrumDivision of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Brooke E HowittDivision of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA. bhowitt@stanford.edu.
Brigham and Women's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small cell carcinoma of the ovary, hypercalcemic type is a rare, aggressive malignancy which usually occurs in young women and is characterized by mutations in SMARCA4, with few other alterations. We recently encountered uterine tumors with morphologic, immunohistochemical, and genetic similarities to small cell carcinoma of the ovary, hypercalcemic type. Herein we report the clinicopathologic and molecular features (using a targeted massively parallel sequencing [MPS] assay) of these tumors. The cases were diagnosed on cervical and endometrial biopsies (n = 2, 34, and 29 years) or hysterectomy and bilateral salpingo-oophorectomy (n = 3, 25, 33, and 58 years). The tumors were composed of sheets of large atypical epithelioid cells with prominent rhabdoid morphology, indistinguishable from the "large cell" variant of small cell carcinoma of the ovary, hypercalcemic type. In three cases, the ovaries were pathologically examined to exclude a primary ovarian malignancy. Immunohistochemically, four of four cases showed SMARCA4 loss, and were negative or only focally positive for keratins, EMA, and claudin-4. One of three cases was positive for WT-1. Targeted MPS was successfully performed on 4 of 5 tumors, and showed recurrent mutations in SMARCA4, with few other alterations. Of the cases diagnosed on hysterectomy, all had extensive lymphovascular invasion, extra-uterine spread, and marked infiltrative growth. These tumors were uniformly aggressive; all patients died of disease (median survival 7 months, range 1-43 months). We propose this entity be called "SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus)", a term which describes both the tumor's underlying molecular abnormality and its morphology. Its unique clinicopathologic and molecular features differentiate it from other related malignancies, including undifferentiated endometrial carcinoma, small cell carcinoma of the ovary (hypercalcemic type), and epithelioid sarcoma. We review and discuss previously reported "rhabdoid tumors of the uterus;" while they are a heterogenous group of tumors, some of them are likely examples of this entity. Correctly identifying cases of SMARCA4-deficient uterine sarcoma from histologic mimics is important as it may have prognostic, predictive, and germline implications.

Indexed as

MutationAdultCarcinomaDNA HelicasesFemaleHumansImmunohistochemistryMiddle AgedNuclear ProteinsPrognosisRhabdoid TumorSurvival RateTranscription FactorsUterine NeoplasmsUterusDNA HelicasesNuclear ProteinsSMARCA4 protein, humanTranscription Factors

Identifiers

PMID29700418
OpenAlexW2801965474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.